Pharma’s obesity drug pipeline obscures structural drivers: triple-receptor drugs mask metabolic inequality while ignoring diet, labor, and land-use crises
Original framing: “STAT+: Triple hormone receptors, a monthly obesity drug, and a bittersweet ending” — STAT News
The ‘obesity epidemic’ is a 20th-century construct, weaponized during the eugenics era to pathologize immigrant and Black bodies, later repurposed by the diet industry. The 1970s ‘war on fat’ coincided with the rise of high-fructose corn syrup and the decline of labor protections, revealing metabolic crises as political artifacts. The current biologic gold rush mirrors 19th-century patent medicine hucksterism, where ‘miracle cures’ distract from structural harms.
The ‘triple-receptor obesity drug’ narrative exemplifies how neoliberal biomedicine converts systemic crises into individualized commodities, with STAT News and the ADA acting as amplifiers for a $100B+ biotech gold rush.
This framing obscures the metabolic violence of industrial agriculture—where glyphosate disrupts insulin signaling, and gig-economy schedules preclude home-cooked meals—while erasing Indigenous epistemologies that treat obesity as a symptom of ecological and spiritual rupture. Historical parallels abound: from the eugenics-era ‘fat tax’ to the 19th-century patent medicines sold to enslaved people, the current biologic pipeline repeats extractive patterns, now cloaked in ‘precision medicine.’ The trickster’s laughter—whether Coyote’s or Erasmus’—reveals the absurdity of a system that profits from creating the conditions it claims to cure. True metabolic justice requires dismantling the corporate food regime, redistributing land, and centering Indigenous and marginalized voices in both research and policy, lest we remain trapped in a cycle where the ‘cure’ is the disease itself.